CSBR

Champions Oncology, Inc. (CSBR) Risks & Opportunities Analysis (2026)

Invetso Score: 7.2/10 — Strong · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Opportunities

Score: 7.7 (Strong)

Champions Oncology is capitalizing on strong demand for high-margin oncology research services, delivering consistent revenue growth and a return to positive adjusted EBITDA. These factors position the company ahead of many small-cap CRO peers and support a favorable long-term growth outlook.

Risks

Score:

Champions Oncology faces moderate risk from tight liquidity, elevated leverage, and potential macro-driven demand volatility. While operational performance is strong, these financial constraints could limit resilience if market or client conditions deteriorate.

Overall Score

Score:

Champions Oncology demonstrates strong operational momentum with high-margin growth and a return to positive EBITDA, offset by moderate liquidity and leverage risks. The company’s financial and market positioning is favorable relative to small-cap CRO peers, but ongoing balance sheet vigilance is warranted.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Champions Oncology, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →